Bank of Montreal Can Sells 83,076 Shares of Zoetis Inc. $ZTS

Bank of Montreal Can reduced its stake in shares of Zoetis Inc. (NYSE:ZTS) by 10.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 698,265 shares of the company’s stock after selling 83,076 shares during the quarter. Bank of Montreal Can owned approximately 0.16% of Zoetis worth $102,170,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. North Star Asset Management Inc. lifted its position in Zoetis by 4.9% during the second quarter. North Star Asset Management Inc. now owns 1,441 shares of the company’s stock valued at $225,000 after acquiring an additional 67 shares during the last quarter. Bank of Nova Scotia Trust Co. boosted its stake in Zoetis by 4.6% in the second quarter. Bank of Nova Scotia Trust Co. now owns 1,692 shares of the company’s stock valued at $264,000 after acquiring an additional 74 shares in the last quarter. Summit Place Financial Advisors LLC grew its holdings in Zoetis by 0.4% in the third quarter. Summit Place Financial Advisors LLC now owns 19,369 shares of the company’s stock worth $2,834,000 after purchasing an additional 76 shares during the last quarter. First County Bank CT increased its position in shares of Zoetis by 5.4% during the third quarter. First County Bank CT now owns 1,535 shares of the company’s stock worth $225,000 after purchasing an additional 79 shares in the last quarter. Finally, Ironwood Investment Counsel LLC increased its position in shares of Zoetis by 1.5% during the second quarter. Ironwood Investment Counsel LLC now owns 5,537 shares of the company’s stock worth $864,000 after purchasing an additional 80 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on ZTS shares. Piper Sandler reissued a “neutral” rating and issued a $135.00 price objective (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. BTIG Research reissued a “buy” rating and issued a $160.00 price target on shares of Zoetis in a report on Thursday, February 26th. Stifel Nicolaus dropped their price target on Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a research note on Tuesday, November 18th. Bank of America increased their price objective on shares of Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research report on Friday, February 13th. Finally, KeyCorp began coverage on shares of Zoetis in a research report on Thursday, November 20th. They issued a “sector weight” rating for the company. Six investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $152.91.

Zoetis Stock Performance

Shares of ZTS stock opened at $119.82 on Thursday. The business has a fifty day moving average of $125.75 and a 200 day moving average of $132.31. Zoetis Inc. has a 1 year low of $115.25 and a 1 year high of $172.23. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. The firm has a market capitalization of $50.58 billion, a price-to-earnings ratio of 19.90, a price-to-earnings-growth ratio of 1.84 and a beta of 0.95.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The business had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. During the same quarter in the previous year, the business earned $1.40 EPS. The company’s quarterly revenue was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a yield of 1.8%. Zoetis’s dividend payout ratio (DPR) is currently 35.22%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.